AlphAIAlphAI — Financial news for AI agents
investing.com$CMPS

Oppenheimer reiterates Compass Pathways stock rating on NDA filing

Oppenheimer maintained an Outperform rating and $20 price target for Compass Pathways (CMPS) after its Q3 update. The company expects to file an NDA for COMP360 within two weeks, aiming for a 2027 launch. CMPS reported $56M in operating expenses, $444M in cash, and a Q3 loss of $0.31 per share, beating estimates. Analysts from TD Cowen, BTIG, and Stifel also reiterated Buy ratings with higher price targets, citing strong execution and trial results.

Original reporting
investing.com
Published Nov 3, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CMPS
Bullish
high confidence
Mentioned
$CMPS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CMPSBullishHigh
01

Why it matters

The analyst upgrade and price target lift the stock's near‑term outlook, while the upcoming NDA filing adds a catalyst that could drive further moves.

02

Market read

New rating and price target provide a clear actionable signal for traders; the upcoming NDA filing could amplify price movement.

03

What to watch

Potential delays in FDA review or DEA rescheduling could dampen the upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Compass Pathways is a Nasdaq‑listed biotech developing COMP360, a psilocybin‑based treatment for treatment‑resistant depression.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

Oppenheimer reiterated an Outperform rating and set a $20 price target after Compass Pathways reported a smaller-than-expected Q3 loss and highlighted an upcoming NDA filing for COMP360.

Expected impact

likely upward pressure as investors price in the rating upgrade and the $20 target.

Evidence & confidence

The rating change and price target are new, and the loss beat reduces downside risk while the pending NDA adds upside catalyst.

Market effects

Sector

Positive signal for the biotech/psychedelic therapy sector as a peer shows progress toward FDA approval.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Modest, confined to investors tracking psychedelic drug pipelines.

Counterpoint

What could challenge this read

The pending NDA filing still carries regulatory risk; the market may have priced in optimism prematurely.

Key entities

  • company
    Compass Pathways

    Biotech firm developing COMP360.

  • analyst
    Oppenheimer

    Equity research firm issuing the rating.

Read at source← All news

StoryCompass Pathways reports Q3 2026 loss, strong cash and prepares NDA filing for COMP360 launch

Also covered by

5 outlets

Related articles

$CMPSHighAI 9/10

Compass Pathways stock gains on FDA filing for depression drug

Compass Pathways (CMPS) shares rose 4.5% after submitting a New Drug Application to the FDA for its psilocybin-based depression treatment, COMP360. The submission is backed by positive Phase 3 trial data. The company expects a potential launch in early 2027, pending FDA approval. Jefferies reiterated a Buy rating and $18.00 price target, citing high confidence in FDA approval.

investing.com
$CMPSMedAI 8/10

Compass Pathfinder Limited: Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

Compass Pathways (CMPS) submitted a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin to treat treatment-resistant depression (TRD). The submission is backed by data from Phase 3 trials and a Phase 2b study involving over 1,000 participants. The company aims for a potential launch in the first half of 2027, pending FDA approval.

finanznachrichten.de
$CMPSMed

Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript

Compass Pathways (CMPS) expects to complete its NDA submission for COMP360 in two weeks, with a potential rapid approval due to a National Priority Voucher. The company has $444M in cash and is preparing for a 2027 launch, targeting treatment-resistant depression (TRD) and exploring PTSD as a label expansion. Management expressed confidence in COMP360's efficacy and market potential, citing positive clinical data and strong commercial team.

finance.yahoo.com